COVID-19 Therapeutics Clinical Review Panel

The Department of Health and Social Care Therapeutics Clinical Review Panel determined which at-risk patient cohorts could be eligible for COVID-19 therapies.

This group has closed

In line with the government’s strategy of living with COVID-19, the COVID-19 Therapeutics Clinical Review Panel closed on 31 March 2023. The most recent reports reviewed by the panel are below.

Role

The panel provided advice on the definition and revision of eligible cohorts for new COVID-19 therapeutics from December 2021 to March 2023. This included a process to provide advice on questions from patient and clinician stakeholders, through a nominated clinician representing a group or individual.

The panel was formed of senior clinicians from all 4 nations. It provided advice to the 4 UK Chief Medical Officers for agreement of the UK clinical policy.

More information on NHS COVID-19 treatments can be found on the NHS website.

Access to COVID-19 antiviral and antibody treatments is currently for patients at high risk from COVID-19, who have conditions set out in the current clinical access policy.

Membership

The panel members were:

  • Professor James Palmer, National Medical Director Specialised Services, NHSEI (chair)

  • Dr Kiren Collison, Medical Director Primary Care, NHS England

  • Dr Chris Streather, Regional Medical Director, NHS England

  • Dr James Coulson, Consultant Physician, Clinical Pharmacologist and Toxicologist and Clinical Director of the All-Wales Therapeutics and Toxicology Centre

  • Professor Thomas Evans, Institute of Infection, Immunity and Inflammation, University of Glasgow

  • Dr Mark Cross Deputy Medical Director Risk and Governance, Belfast Health and Social Care Trust

  • Dr Matthew Boulter, Senior Clinical Adviser, UKHSA

  • Dr Nevila Kallfa, Adviser in Public Health Medicine, UKHSA

  • Professor Jonathan Benger, Chief Medical Officer, NHS Digital, Professor of Emergency Care, Consultant in Emergency Medicine, University Hospitals Bristol and Weston

Terms of reference

Terms of reference

PDF, 39.5 KB, 2 pages

Governance

The Antivirals and Therapeutics Taskforce at the Department of Health and Social Care provided secretariat support.

Reports reviewed by the panel

Pre-exposure prophylaxis (PrEP) and COVID-19: independent advisory group report (published 31 March 2023)

Therapeutics Clinical Review Panel (TCRP) modelling group findings: risk of severe COVID-19 outcomes (published 31 March 2023)

Higher-risk patients eligible for COVID-19 treatments: independent advisory group report, March 2023 (published 31 March 2023)

Higher-risk patients eligible for COVID-19 treatments: independent advisory group report (published 30 May 2022)

Contents